Medtronic plc (MDT) recently secured the FDA’s approval for the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. The latest Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access.The latest development will significantly boost the Coronary & Renal Denervation and Structural Heart & Aortic businesses, which are part of Medtronic’s Cardiovascular por ...

If you're an everyday investor looking for stocks that can deliver steadily rising dividend payouts over long periods, the healthcare sector is the right place to begin your search. People get sick during economic downturns just as often as they do when businesses are booming.Medtronic (MDT 0.27%) and Walgreens Boots Alliance (WBA 3.19%) are two dividend-paying giants of the healthcare sector. Both offer yields that are far more attractive than the paltry 1.4% yield you can receive from the average stock in ...

When you think of artificial intelligence (AI), you probably think of the technology companies creating the nuts and bolts that help AI come to life -- such as Nvidia's chips or Super Micro Computer's servers. We've already seen growth in these companies' earnings thanks to sales of their products to customers developing AI projects. They and some of their peers continue to make great investments because growth in the AI market looks like it's just getting started.But there's another way to invest in AI, an ...

Medtronic moves for patent infringement litigation to resume DUBLIN, March 21, 2024  /PRNewswire/ -- Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has affirmed the validity of claims in two of its patents in an ongoing patent infringement lawsuit filed by Medtronic against Axonics over sacral neuromodulation (SNM) technologies. Cumulatively, the PTAB has now upheld the validity of five o ...

Investors are enjoying the ongoing bull run. The S&P 500 and Nasdaq Composite recently hit all-time highs. Though that's pretty exciting, bull markets don't last forever. Equities that can perform well in good times are great. Those that can perform well over the long run, through bull and bear markets, economic peaks and lows, are even better.Let's look at two excellent stocks that ought to deliver solid returns well beyond the current bull market: Medtronic (MDT 0.31%) and Merck (MRK -0.03%).1. MedtronicM ...

“Higher for longer” may prove true as sticky inflation indicates the higher-rate environment might be here to stay. As interest rates stay steady, risk-averse investors gravitate towards short-term Treasuries for safety. However, a handful of stocks for high-interest rates are stepping into the limelight for those seeking a blend of excitement and potential upside. Dividend-paying and high-yield stocks present an attractive mix of predictable income and the thrill of market dynamics without compromising the ...

New pharmacokinetic data demonstrate Virtue® SAB enables extended release of sirolimus above required tissue concentrations in target arterial sites without polymer degradation or detectable remaining polymer within 90 days of balloon deliveryAVIM therapy presentation highlighted recent clinical results showing favorable hemodynamic effects and long-term reduction in 24-hour ambulatory systolic blood pressure, as well as the design of the BACKBEAT global pivotal study now enrolling in collaboration with Med ...

Medtronic plc (NYSE:MDT) 2024 Barclays 26th Annual Healthcare Conference Call March 12, 2024 8:00 AM ET Company Participants Karen Parkhill - CFO Conference Call Participants Matt Miksic - Barclays Matt Miksic Good morning. Thanks so much for joining us. My name is Matt Miksic, I’m US Medical Device Analyst here at Barclays, and we are very pleased to have with us today Medtronic, specifically, CFO, Karen Parkhill, so thanks again so much for joining us. Karen Parkhill Thank you, Matt. Great to be here. Mat ...

Financial Data and Key Metrics Changes - The company has delivered mid-single-digit topline growth for five consecutive quarters, indicating a clear turnaround in revenue performance [2] - The guidance for Q4 implies continued mid-single-digit topline growth, reflecting confidence in sustaining this growth trajectory [2] Business Line Data and Key Metrics Changes - The diabetes segment has shown significant improvement, with over 10% growth globally in the last quarter, driven by the 780G pump and the new Simplera Sync sensor [4] - Cardiac ablation is expected to be a long-term growth driver, with the PulseSelect catheter and Affera system set to launch, which are anticipated to enhance market share [10][11] Market Data and Key Metrics Changes - The company expects the vast majority of the Value-Based Pricing (VBP) impact in China to be behind them by the end of the fiscal year, reducing future headwinds [16] - The EV-ICD product is entering a growing market, projected to reach $300 million, which is expected to drive long-term growth [19] Company Strategy and Development Direction - The company is focused on a performance-driven culture, emphasizing execution and delivering on commitments, which is reflected in their financial results [2] - There is a strong emphasis on innovation in diabetes management, with plans for NextGen algorithms and sensors, indicating a commitment to maintaining competitive advantage [6] - The company is balancing shareholder returns with investments in growth, maintaining a strong and growing dividend while also authorizing share repurchases [33] Management's Comments on Operating Environment and Future Outlook - Management expressed strong confidence in the future, highlighting a durable mid-single-digit topline growth and a focus on driving earnings power [29][36] - The company acknowledges headwinds from currency fluctuations, global tax reform, and inflation, but remains focused on cost management and pricing strategies to mitigate these impacts [31] Other Important Information - The company is actively working on expanding its surgical robot, Hugo, into various surgical fields and is adapting its go-to-market strategy to meet customer needs without competing solely on price [25] Q&A Session Summary Question: Discussion on diabetes product growth and future expectations - Management highlighted a significant turnaround in the diabetes business, with strong growth in the US and plans for new product launches [4] Question: Expectations for cardiac ablation product launches - Management expects growth from the PulseSelect and Affera systems, with positive feedback from physicians and plans for data announcements [10][11] Question: Impact of VBP in China on top-line growth - Management indicated that most of the VBP impact is behind them, with minor delays in specific product areas [16] Question: Updates on EV-ICD product launch - Management described the EV-ICD as a long-term growth driver, emphasizing its market potential and differentiation [19] Question: Insights on the SMART trial data and competitive positioning - Management expressed confidence in the upcoming trial results and their potential to enhance market share in the competitive structural heart market [23] Question: Strategy for the surgical robot market - Management discussed the positive feedback for the Hugo robot and their flexible financing options to meet customer needs [25]

Medtronic plc (MDT) is likely to grow in the coming quarters, backed by remarkable progress within the Cardiovascular portfolio. The Cranial and Spinal technologies business within the company’s Neuroscience portfolio has been registering strong growth in recent quarters. Favorable solvency is highly encouraging.Meanwhile, macroeconomic challenges may have an adverse impact on the company’s operations. Intense competition from peers is also concerning.In the past year, this Zacks Rank #3 (Hold) stock has in ...